Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
27.2M
-
Number of holders
-
52
-
Total 13F shares, excl. options
-
10.6M
-
Shares change
-
+322K
-
Total reported value, excl. options
-
$33.5M
-
Value change
-
+$1.18M
-
Number of buys
-
16
-
Number of sells
-
-15
-
Price
-
$3.15
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q2 2023
61 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q2 2023.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10.6M shares
of 27.2M outstanding shares and own 39.06% of the company stock.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (2.12M shares), Artal Group S.A. (1.48M shares), Avidity Partners Management LP (1.46M shares), Flagship Pioneering Inc. (994K shares), Samsara BioCapital, LLC (881K shares), CHI Advisors LLC (767K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (722K shares), VANGUARD GROUP INC (497K shares), DAFNA Capital Management LLC (266K shares), and Omega Fund Management, LLC (251K shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.